In vitro evaluation of valproic acid as an inhibitor of human cytochrome P450 isoforms: preferential inhibition of cytochrome P450 2C9 (CYP2C9)
about
PharmGKB summary: very important pharmacogene information for cytochrome P-450, family 2, subfamily A, polypeptide 6Histone deacetylase inhibitor valproic acid promotes the differentiation of human induced pluripotent stem cells into hepatocyte-like cellsInteraction of valproic acid and the antidepressant drugs doxepin and venlafaxine: analysis of therapeutic drug monitoring data under naturalistic conditions.Drug-drug interactions between warfarin and psychotropics: updated review of the literature.An unexpected increase of entropy in a sleepwalking disorder patient during propofol and remifentanil anesthesia: a case reportMechanisms of pharmacokinetic and pharmacodynamic drug interactions associated with ritonavir-enhanced tipranavir.Update: new uses for lithium and anticonvulsants.The impact of the use of antiepileptic drugs on the growth of childrenRequired propofol dose for anesthesia and time to emerge are affected by the use of antiepileptics: prospective cohort study.Anticonvulsant and antiretroviral interactions.Drug bioactivation, covalent binding to target proteins and toxicity relevance.Relationship of ketamine's plasma metabolites with response, diagnosis, and side effects in major depression.Time-dependent CYP inhibition.Neuroendocrine considerations in the treatment of men and women with epilepsyMoclobemide monotherapy vs. combined therapy with valproic acid or carbamazepine in depressive patients: a pharmacokinetic interaction study.Valproic Acid, a Histone Deacetylase Inhibitor, in Combination with Paclitaxel for Anaplastic Thyroid Cancer: Results of a Multicenter Randomized Controlled Phase II/III Trial.Influence of enzyme-inducing antiepileptic drugs on trough level of imatinib in glioblastoma patients.Influence of valproate on the required dose of propofol for anesthesia during electroconvulsive therapy of bipolar affective disorder patients.Detrimental effects of divalproex on warfarin therapy following mechanical valve replacement.Cardiac arrhythmias and sudden unexpected death in epilepsy (SUDEP).Clinically significant drug interactions with atypical antipsychotics.Interactions between valproic acid and quetiapine/olanzapine in the treatment of bipolar disorder and the role of therapeutic drug monitoring.Development of individualized medicine for epilepsy based on genetic information.Antiepileptic drugs in patients with malignant brain tumor: beyond seizures and pharmacokinetics.Markers of bone turnover in patients with epilepsy and their relationship to management of bone diseases induced by antiepileptic drugs.Brivaracetam population pharmacokinetics in children with epilepsy aged 1 month to 16 years.Histone deacetylase inhibitors valproate and trichostatin A are toxic to neuroblastoma cells and modulate cytochrome P450 1A1, 1B1 and 3A4 expression in these cells.Influence of CYP2C9 polymorphism on metabolism of valproate and its hepatotoxin metabolite in Iranian patients.Effect of sodium valproate on nocturnal melatonin sensitivity to light in healthy volunteers.Urinary 6-hydroxymelatonin sulfate excretion in intellectually disabled subjects with sleep disorders and multiple medications: validation of measurements in urine extracted from diapers.Effect of carbamazepine or phenytoin therapy on blood level of intravenously administered midazolam: a prospective cohort study.The influence of oral VPA on the required dose of propofol for sedation during dental treatment in patients with mental retardation: a prospective observer-blinded cohort study.Apixaban Concentration with and without Coadministration of Carbamazepine: A Case with No Apparent Interaction.Drug-Drug Interaction Studies of Paliperidone and Divalproex Sodium Extended-Release Tablets in Healthy Participants and Patients with Psychiatric Disorders.Drug-drug interaction between clobazam and cannabidiol in children with refractory epilepsy.Probable Interaction Between Warfarin and Divalproex Sodium.
P2860
Q27012807-B5EB1BE8-1BA3-4B52-A899-AE9D3D8F8CDFQ28541550-39ECE490-C4D4-4430-9373-1058A85EB72AQ30724630-493621E0-DB38-4D9C-9857-3BE461D3E03FQ34432843-A2C78E29-6D1F-441B-BD32-53B5401D9008Q34438665-3DDA2829-B48B-4C73-A969-53C6B7FD4204Q34633457-03FC52B4-6290-4622-93D7-60939277CD5EQ34710521-CC06797E-0F0F-4636-99FA-95113CC13493Q35071970-ACAAD515-7133-4520-AEFF-F44958D72D58Q35191123-8C81D06C-98F2-4386-8CE2-52D0D59F5BDAQ35670044-0A832A86-7E3D-4D58-A4C5-726D18A09D62Q36061821-B78FCD4B-8462-40A6-B74B-81DA0EF8F3BEQ36233963-8AAA20DC-5B77-40B3-9F8F-BCB1DBA7E0E3Q36725214-726E2423-0785-440C-B078-354D90F03CC3Q37055791-ADA289DA-0650-46CF-8EEF-6C79D71EDB39Q37161513-45543EA0-5012-48B7-9FEC-0285D9D1C104Q37330090-936CF143-4B7B-45DE-B1E1-28FF1B63B8CFQ37357178-D5B2BC34-6D61-4E8E-BCB6-C79D02888BAAQ37630496-BDCA12E6-2B32-4EA3-B3E3-94FCFBFF7425Q37920925-059C31FC-8A00-41EB-8C3C-21E6E6BB9DB9Q37962593-869513E5-3BFB-49A6-BE9C-7196DCD1ECDEQ38156416-AF21AF5A-00A2-4694-972D-D3E7B3B35D23Q38176041-C7CBECE7-0795-49D6-A620-ECAC376F0F35Q38178326-6FBADB6B-8876-4364-9DE9-B48CB66D07C0Q38495389-C48DEF54-F9B1-4049-A4D2-4040D794F819Q38640619-10E8C190-A402-43B8-AD58-21621CDCC1AFQ38915714-8E462D86-A2B5-4378-96DF-780A019F7754Q39806900-D7002FD2-6AC9-459E-AFBA-E2C0E1A74DE5Q42985549-FBCF85FF-FC1C-42AB-9A4F-C62DA508FFFBQ46446306-8388A09E-D3C5-4FD6-AD69-50010828A045Q46635566-8EBC8C04-0DBC-4B40-A9A3-682EB3B4DA80Q47664067-BB48DAF6-3690-4169-B9E0-FB812A7DF71EQ48213535-A23D5183-3124-441B-A000-F35D391673FCQ49335499-94FFF2BB-97D0-424A-9EBD-C53DE1A9A9B8Q50562638-F25D40DF-E82D-400F-83F9-404378431F95Q53835626-CF8FDB62-0289-49E6-ABB8-2B05C65EA273Q55283403-350F211C-4B5F-42EF-9910-BE6577EF03A8
P2860
In vitro evaluation of valproic acid as an inhibitor of human cytochrome P450 isoforms: preferential inhibition of cytochrome P450 2C9 (CYP2C9)
description
2001 nî lūn-bûn
@nan
2001 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
In vitro evaluation of valproi ...... f cytochrome P450 2C9 (CYP2C9)
@ast
In vitro evaluation of valproi ...... f cytochrome P450 2C9 (CYP2C9)
@en
In vitro evaluation of valproi ...... f cytochrome P450 2C9 (CYP2C9)
@nl
type
label
In vitro evaluation of valproi ...... f cytochrome P450 2C9 (CYP2C9)
@ast
In vitro evaluation of valproi ...... f cytochrome P450 2C9 (CYP2C9)
@en
In vitro evaluation of valproi ...... f cytochrome P450 2C9 (CYP2C9)
@nl
prefLabel
In vitro evaluation of valproi ...... f cytochrome P450 2C9 (CYP2C9)
@ast
In vitro evaluation of valproi ...... f cytochrome P450 2C9 (CYP2C9)
@en
In vitro evaluation of valproi ...... f cytochrome P450 2C9 (CYP2C9)
@nl
P2093
P2860
P3181
P1476
In vitro evaluation of valproi ...... f cytochrome P450 2C9 (CYP2C9)
@en
P2093
P2860
P304
P3181
P356
10.1046/J.0306-5251.2001.01474.X
P407
P577
2001-11-01T00:00:00Z